| 2025-11-20 |
详情>>
业绩披露：
2026年中报每股收益-1.88美元,归母净利润-199.27万美元,同比去年增长-167.31%
|
| 2025-10-06 |
详情>>
股本变动：
变动后总股本187.21万股
|
| 2025-08-02 |
复牌提示：
2025-08-01 15:53:50 停牌，复牌日期 2025-08-01 16:00:00
|
| 2025-06-25 |
详情>>
业绩披露：
2023年年报每股收益-394.06美元,归母净利润-320.64万美元,同比去年增长-140.01%
|
| 2025-06-25 |
详情>>
业绩披露：
2025年年报每股收益5.24美元,归母净利润101.18万美元,同比去年增长101.98%
|
| 2025-05-05 |
详情>>
拆分方案：
每7.9700合并分成1.0000股
|
| 2025-03-31 |
股东大会：
将于2025-04-16召开股东大会
会议内容 ▼▲
- 1.To consider and, if deemed appropriate, to pass, with or without variation, a special resolution approving the proposed consolidation of the common shares of the Corporation;
2.To transact such other business as may properly come before the Meeting.
|
| 2024-11-26 |
详情>>
拆分方案：
每75.0000合并分成1.0000股
|
| 2024-10-23 |
股东大会：
将于2024-11-12召开股东大会
会议内容 ▼▲
- 1.To receive and consider the audited financial statements of the Corporation as at and for the year ended March 31, 2024, together with the report of the auditors thereon;
2.The appointment of MNP LLP as the auditor of the Corporation and to authorize the directors to fix their remuneration;
3.The election of directors of the Corporation;
4.An ordinary resolution authorizing and approving the adoption of amendments to the Psyence Biomedical Ltd 2023 Equity Incentive Plan to (i) increase the number of shares reserved for issuance under the plan by 6,141,527 common shares, and (ii) allow for an automatic increase of the common shares available for issuance under the plan to an amount equal to 15% of the then issued and outstanding common shares of the Corporation;
5.A special resolution approving the proposed consolidation of the common shares of the Corporation;
|
| 2024-01-31 |
详情>>
业绩披露：
2024年中报每股收益-0.25美元,归母净利润-215.6万美元,同比去年增长-2368.75%
|
| 2024-01-22 |
股东大会：
将于2024-01-22召开股东大会
会议内容 ▼▲
- 1.A proposal, by special resolution, to extend the date by which the Company must consummate an initial business combination by one month from January 22, 2024 to February 22, 2024 (which is 28 months from the closing of our initial public offering (the “IPO”)) (which extension and later date we refer to as the “Extension” and the “Extended Date,” respectively) by amending the Company’s Amended and Restated Memorandum and Articles of Association, as provided by the first resolution in the form set forth in Annex A to the accompanying proxy statement (the “Extension Amendment” and such proposal, the “Extension Amendment Proposal”);
2.A proposal, by the affirmative vote of at least sixty-five percent (65%) of the outstanding Class A Ordinary Shares and Class B Ordinary Shares, voting together as a single class, to amend that certain investment management trust agreement, dated as of October 19, 2021, as amended on January 6, 2023 and July 11, 2023 (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company (the “Trustee”), to allow the Company to extend the Combination Period by one month from January 22, 2024 to February 22, 2024 (the “Trust Agreement Amendment,” and such proposal, the “Trust Agreement Amendment Proposal”);
3.A proposal, by ordinary resolution, to adjourn the EGM to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the EGM, there are insufficient votes to approve the Extension Amendment Proposal and the Trust Agreement Amendment Proposal (the “Adjournment Proposal” and, together with the Extension Amendment Proposal and the Trust Agreement Amendment Proposal, the “Proposals”).
|
| 2023-11-21 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.49美元,归母净利润-73.51万美元,同比去年增长-112.75%
|
| 2023-11-15 |
股东大会：
将于2023-11-30召开股东大会
会议内容 ▼▲
- 1.The Business Combination Proposal: to consider and vote upon a proposal, by ordinary resolution, to approve and adopt the Amended and Restated Business Combination Agreement, dated as of July 31, 2023 (as amended, supplemented, or otherwise modified from time to time, the “Business Combination Agreement”), by and among NCAC, Newcourt SPAC Sponsor LLC, a Delaware limited liability company (“Sponsor”), Psyence Group Inc., a corporation organized under the laws of Ontario, Canada (“Parent”), Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (“Pubco”), Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a direct and wholly owned subsidiary of Pubco (“Merger Sub”), Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada, and Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (“Psyence”), pursuant to which each of the following transactions will occur in the following order:(a)Parent will contribute Psyence to Pubco in a share for share exchange (the “Company Exchange”); (b)immediately following the Company Exchange, Merger Sub will merge with and into NCAC, with NCAC being the surviving company in the merger (the “Merger”) and each outstanding ordinary share of NCAC (“NCAC Ordinary Shares”) will convert into the right to receive one common share of Pubco (“Pubco Common Share”).
2.The Merger Proposal: to approve, by special resolution:(a)NCAC be authorized to merge with Merger Sub, so that NCAC be the surviving company and all undertaking, property and liabilities of Merger Sub vest in NCAC by virtue of the Merger in accordance with the Business Combination Agreement and the Companies Act (As Revised) of the Cayman Islands (the “Companies Act”);(b)the Plan of Merger in the form attached to the accompanying proxy statement/prospectus as Annex D (the “Plan of Merger”), pursuant to which NCAC will merge with Merger Sub, with NCAC being the surviving company;(c)NCAC be authorized to enter into the Plan of Merger;
3.The Organizational Documents Proposal: to consider and vote upon a proposal to approve, by special resolution under Cayman Islands law, assuming the Business Combination Proposal and Merger Proposal are approved and adopted, the approval of the articles of incorporation and amended and restated by-laws (together, the “Proposed Articles”) of Pubco, which, if approved, would take effect at the time of the Closing (we refer to this proposal as the “Organizational Documents Proposal”);
4.The Advisory Articles Proposals: to consider and vote, on an advisory and non-binding basis, on three separate sub-proposals to approve certain governance provisions in the Proposed Articles. These separate votes are not otherwise required by under Cayman Islands law, separate and apart from the Organizational Documents Proposal, but are required by SEC guidance requiring that stockholders have the opportunity to present their views on important corporate governance provisions (we refer to these proposals as the “Advisory Articles Proposals”)(a)Advisory Articles Proposal 4A: To approve, on an advisory and non-binding basis, provisions to be included in the Proposed Articles which establish the authorized capital of Pubco to consist of an unlimited number of common shares.(b)Advisory Articles Proposal 4B: To approve, on an advisory and non-binding basis, provisions to be included in the Proposed Articles which establish Pubco’s corporate name as “Psyence Biomedical Ltd.”(c)Advisory Articles Proposal 4C: To approve, on an advisory and non-binding basis, the exclusion from the Proposed Articles of certain provisions related to NCAC’s status as a blank check company that will not apply to Pubco upon consummation of the Business Combination.
5.The Incentive Plan Proposal: to consider and vote upon a proposal to approve by ordinary resolution under Cayman Islands law, the Pubco 2023 Equity Incentive Plan (the “Incentive Plan”), a copy of which is attached to this proxy statement/prospectus as Annex E (we refer to this proposal as the “Incentive Plan Proposal”);
6.The Director Proposal: to consider and vote upon, by ordinary resolution, the appointment of five (5) directors, who, upon consummation of the Business Combination, will constitute all the members of the Pubco Board (we refer to this proposal as the “Director Proposal”);
7.The Shareholder Adjournment Proposal: to consider and vote upon a proposal, by ordinary resolution, to adjourn the special meeting to a later date or dates, if necessary or appropriate, as determined by the NCAC Board (the “Shareholder Adjournment Proposal”).
|
| 2023-09-20 |
详情>>
业绩披露：
2023年一季报每股收益0.15美元,归母净利润-2.45万美元,同比去年增长-100.83%
|
| 2023-09-20 |
详情>>
业绩披露：
2023年中报每股收益0.36美元,归母净利润-8.73万美元,同比去年增长-101.75%
|
| 2023-09-20 |
详情>>
业绩披露：
2022年年报每股收益0.38美元,归母净利润801.43万美元,同比去年增长-2.63%
|
| 2023-06-23 |
股东大会：
将于2023-07-11召开股东大会
会议内容 ▼▲
- 1.A proposal, by special resolution, to extend the date by which the Company must consummate an initial business combination up to six (6) times for one (1) month each time from July 22, 2023 to January 22, 2024 (which is 27 months from the closing of our initial public offering (the “IPO”)) (which extension and later date we refer to as the “Extension” and the “Extended Date,” respectively) by amending the Company’s Amended and Restated Memorandum and Articles of Association, as provided by the first resolution in the form set forth in Annex A to the accompanying proxy statement (the “Extension Amendment” and such proposal, the “Extension Amendment Proposal”);
2.A proposal, by special resolution, to amend the Company’s Amended and Restated Memorandum and Articles of Association, as provided by the second resolution in the form set forth in Annex A to the accompanying proxy statement (the “Redemption Limitation Amendment” and such proposal, the “Redemption Limitation Amendment Proposal”) to eliminate from the Company’s Amended and Restated Memorandum and Articles of Association the limitation that the Company shall not redeem public shares to the extent that such redemption would cause the Company’s net tangible assets to be less than $5,000,001 (the “Redemption Limitation”). The Redemption Limitation Amendment would allow the Company to redeem public shares irrespective of whether such redemption would exceed the Redemption Limitation;
3.A proposal to approve by the affirmative vote of at least sixty-five percent (65%) of the outstanding Class A Ordinary Shares and Class B Ordinary Shares, voting together as a single class, to amend the Company’s investment management trust agreement, dated as of October 19, 2021, as amended on January 6, 2023 (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company (the “Trustee”), to allow the Company to extend the Combination Period up to six (6) times for one (1) month each time from July 22, 2023 to January 22, 2024 (the “Trust Agreement Amendment”) by depositing into the trust account (the “Trust Account”), for each additional one-month extension, the lesser of (a) $45,000 and (b) $0.03 for each Class A ordinary share outstanding (each an “Extension Payment”) after giving effect to the Redemption (the “Trust Agreement Amendment Proposal”);
4.A proposal, by ordinary resolution, to adjourn the EGM to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the EGM, there are insufficient votes to approve the Extension Amendment Proposal, the Redemption Limitation Amendment Proposal and the Trust Agreement Amendment Proposal (the “Adjournment Proposal” and, together with the Extension Amendment Proposal, the Redemption Limitation Amendment Proposal and the Trust Agreement Amendment Proposal, the “Proposals”).
|
| 2022-12-21 |
股东大会：
将于2023-01-06召开股东大会
会议内容 ▼▲
- 1.A proposal, by special resolution to extend the date by which the Company must consummate an initial business combination for an initial three (3) months from January 22, 2023 to April 22, 2023 and up to three (3) times for an additional one (1) month each time from April 22, 2023 to July 22, 2023 (which is 21 months from the closing of our initial public offering (the “IPO”)) (which extension and later date we refer to as the “Extension” and the “Extended Date,” respectively) by amending the Company’s Amended and Restated Memorandum and Articles of Association (the “Extension Amendment Proposal”);
2.A proposal to approve by the affirmative vote of at least sixty-five percent (65%) of the outstanding Class A Ordinary Shares and Class B Ordinary Shares, voting together as a single class, to amend the Company’s investment management trust agreement, dated as of October 19, 2021 (the “Trust Agreement”), by and between the Company and Continental Stock Transfer & Trust Company (the “Trustee”), to allow the Company to extend the Combination Period for an initial three (3) months from January 22, 2023 to April 22, 2023 and up to three (3) times for an additional one (1) month each time from April 22, 2023 to July 22, 2023 (the “Trust Agreement Amendment”) by depositing into the trust account (the “Trust Account”), (i) as soon as practicable after the effective date of the Trust Agreement Amendment, for the initial three-month extension, the lesser of (a) $247,500 and (b) $0.165 for each Class A ordinary share outstanding (the “First Extension Payment”) after giving effect to the Redemption (as defined below), and (ii) for each additional one-month extension, the lesser of (a) $82,500 and (b) $0.055 for each Class A ordinary share outstanding (each a “One-Month Extension Payment”) after giving effect to the Redemption (the “Trust Agreement Amendment Proposal”);
3.A proposal, by ordinary resolution, to adjourn the EGM to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the EGM, there are insufficient votes to approve the Extension Amendment Proposal and the Trust Agreement Amendment Proposal (the “Adjournment Proposal” and, together with the Extension Amendment Proposal and the Trust Agreement Amendment Proposal, the “Proposals”).
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益0.21美元,归母净利润576.39万美元,同比去年增长7350.77%
|
| 2021-10-22 |
详情>>
内部人交易：
Newcourt SPAC Sponsor LLC股份增加920000.00股
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|